Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Neuroprotection for Parkinson's disease: a new approach for a new millennium
Autore:
Drukarch, B; van Muiswinkel, FL;
Indirizzi:
Free Univ Amsterdam, Dept Med Pharmacol, Neurosci Res Inst, Med Ctr, NL-1081 BT Amsterdam, Netherlands Free Univ Amsterdam Amsterdam Netherlands NL-1081 BT terdam, Netherlands
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 10, volume: 10, anno: 2001,
pagine: 1855 - 1868
SICI:
1354-3784(200110)10:10<1855:NFPDAN>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTIOXIDANT RESPONSE ELEMENT; GLUTATHIONE-S-TRANSFERASES; HUMAN SUBSTANTIA-NIGRA; NF-KAPPA-B; DT-DIAPHORASE; ANETHOLE DITHIOLETHIONE; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; NAD(P)H-QUINONE OXIDOREDUCTASE; DOPAMINERGIC-NEURONS;
Keywords:
basal ganglia; detoxification enzymes; gene induction; neurodegeneration; neuromelanin; neuroprotection; oxidative stress; Parkinsons disease; quinone; substantia nigra;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
106
Recensione:
Indirizzi per estratti:
Indirizzo: Drukarch, B Free Univ Amsterdam, Dept Med Pharmacol, Neurosci Res Inst, Med Ctr, Vd Boechorststr 7, NL-1081 BT Amsterdam, Netherlands Free Univ Amsterdam Vd Boechorststr 7 Amsterdam Netherlands NL-1081 BT
Citazione:
B. Drukarch e F.L. van Muiswinkel, "Neuroprotection for Parkinson's disease: a new approach for a new millennium", EXPERT OP I, 10(10), 2001, pp. 1855-1868

Abstract

Parkinson's disease (PD) is the only neurodegenerative disorder in which pharmacological intervention has resulted in a marked decrease in morbidity and a significant delay in mortality. However, the medium to long-term efficacy of this pharmacotherapy, mainly consisting of dopaminomi-metics like L-dopa and dopamine receptor agonists, suffers greatly from the unrelenting progression of the disease process underlying PD, i.e., the degeneration ofneuromelanin-containing, dopaminergic neurones in the substantia nigra. Efforts concentrated on understanding the mechanisms of dopaminergic cell death in Parkinson's disease have led to identification of a large variety of pathogenetic factors, including excessive release of oxygen free radicals during enzymatic dopamine breakdown, impairment of mitochondrial function, production of inflammatory mediators, loss of trophic support, and apoptosis. Therapeutic approaches aimed at correcting these abnormalities are currently being evaluated on their efficacy as neuroprotectants for PD. Here, we focus on the process of dopamine auto-oxidation, the chain of reactions leading to the formation of neuromelanin, as an often overlooked, yet obvious pathogenetic factor. In particular, we discuss the option of drug-mediated stimulation of endogenous mechanisms responsible for the detoxification of dopamine auto-oxidation products as a novel means of neuroprotection in Parkinson's disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 22:04:49